Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?
about
Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesRegulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine.Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain.
P2860
Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?
@en
Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?
@nl
type
label
Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?
@en
Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?
@nl
prefLabel
Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?
@en
Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?
@nl
P2860
P1433
P1476
Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?
@en
P2093
Richard H Hunt
Yuhong Yuan
P2860
P2888
P304
P356
10.1163/156856003322699528
P577
2003-01-01T00:00:00Z
P5875
P6179
1034502470